Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study to Ablate Oligometastatic Deposits by Single Dose Radiotherapy (SDRT) and Metabolic Assessment of Outcome

NCT03543696 is registered in ClinicalTrials.gov with Fundacao Champalimaud as lead sponsor.

NCT NCT03543696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03543696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study to Ablate Oligometastatic Deposits by Single Dose Radiotherapy (SDRT) and Metabolic Assessment of Outcome
Lead sponsor
Fundacao Champalimaud
Phase
Not applicable
Overall status
Completed
Start date
December 1, 2011
Completion date
December 31, 2019
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cancer